“But clearly, we're looking towards end of phase two, end of next year, planning for phase three.”
→ Read the source episode
StepPharma completes ET phase two trial and announces phase three planning by 2027-12-31
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Andy Parker predicts ET trial will recruit 50 patients by summer 2027 and be phase three ready by end of 2027.
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts phase one readout from solid tumor safety expansion cohorts within 12-15 months (by October 2027).
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.